Size | Price | |
---|---|---|
500mg | ||
1g | ||
Other Sizes |
ln Vitro |
A549 cell persistence is dose-dependently lowered by perillic acid (1–5 mM; 24 h) [1]. A549 and H520 cells become inflamed when exposed to 2 mM of perillic acid for 24 hours [1]. Against 17syn+ HSV-1 (EC50 KOS: 2.84 μM; 17syn+: 1.08 μM), perillic acid (0-50 μM; 24 h) exhibits the most antiviral activity [2].
|
---|---|
ln Vivo |
Mice treated with perillic acid (50 μM/kg; ip; once daily for five days) exhibit immunomodulatory action [3].
|
Cell Assay |
Cytotoxicity Assay[1]
Cell Types: A549 Cell Tested Concentrations: 1, 2, 3, 4 and 5 mM Incubation Duration: 24 h Experimental Results: Caused reduction in viability in a dose-dependent manner with an IC50 of 3.6 mM. Cell cycle analysis [1] Cell Types: A549 and H520 Cell Tested Concentrations: 1 mM Incubation Duration: 24 hrs (hours) Experimental Results: Induced S phase arrest in A549 cells and G2/M phase arrest in H520 cells. Apoptosis analysis[1] Cell Types: A549 and H520 Cell Tested Concentrations: 2 mM Incubation Duration: 24 hrs (hours) Experimental Results: Apoptosis increased to 27% in A549 cells and 27% in H520 cells compared to control (12%) Apoptosis increased to 18%. Western Blot Analysis[1] Cell Types: H520 Cell Tested Concentrations: 0.5 mM Incubation Duration: 24 hrs (hours) Experimental Results: Increased Bax expression and diminished procaspase-3 levels. |
Animal Protocol |
Animal/Disease Models: balb/c (Bagg ALBino) mouse [3]
Doses: 50 μM/kg Route of Administration: intraperitoneal (ip) injection, one time/day for 5 days Experimental Results: Increased white blood cell (WBC) count. Total antibody production, antibody-producing cells in the spleen, bone marrow cellularity, and alpha-esterase-positive cells were Dramatically increased compared with normal animals. |
References |
|
Additional Infomation |
Perillic acid is an alpha,beta-unsaturated monocarboxylic acid and a cyclohexenecarboxylic acid. It has a role as an antineoplastic agent, a human metabolite and a mouse metabolite. It is a conjugate acid of a perillate.
Perillic acid has been reported in Perilla frutescens and Homo sapiens with data available. |
Molecular Formula |
C10H14O2
|
---|---|
Exact Mass |
166.099
|
CAS # |
7694-45-3
|
Related CAS # |
(S)-(-)-Perillic acid;23635-14-5
|
PubChem CID |
1256
|
Appearance |
Typically exists as solid at room temperature
|
Density |
1.068 g/cm3
|
Boiling Point |
284.9ºC at 760 mmHg
|
Melting Point |
129-131 °C(lit.)
|
Flash Point |
134ºC
|
Index of Refraction |
1.513
|
LogP |
2.373
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
2
|
Rotatable Bond Count |
2
|
Heavy Atom Count |
12
|
Complexity |
238
|
Defined Atom Stereocenter Count |
0
|
SMILES |
CC(=C)C1CCC(=CC1)C(=O)O
|
InChi Key |
CDSMSBUVCWHORP-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C10H14O2/c1-7(2)8-3-5-9(6-4-8)10(11)12/h5,8H,1,3-4,6H2,2H3,(H,11,12)
|
Chemical Name |
4-prop-1-en-2-ylcyclohexene-1-carboxylic acid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.